<DOC>
	<DOCNO>NCT02459067</DOCNO>
	<brief_summary>To determine safety , tolerability , maximum tolerate dose ( MTD ) efficacy ImmuniCell® patient melanoma , renal cell cancer ( RCC ) non-small cell lung cancer ( NSCLC ) . The study adaptive design 3 stage : Stage 1 - dose escalation , Stage 2 - efficacy , Stage 3 - confirm efficacy one tumor type .</brief_summary>
	<brief_title>ImmuniCell® Patients With Advanced Cancers</brief_title>
	<detailed_description>This open-label trial ImmuniCell® treatment patient malignant melanoma , renal cell cancer ( RCC ) non-small cell lung cancer ( NSCLC ) refractory current treatment indolent disease immunotherapy may beneficial . The trial design identify safe dose ImmuniCell® future clinical trial , identify response signal one cancer investigation confirm safety efficacy select target tumour . The trial three stage : Stage I comprise safety cohort patient identify safe dose Stage II comprise expand patient group response signal identification Stage III confirm efficacy safety .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Male female patient age ≥18 year 2 . Performance status Eastern Cooperative Oncology Group ( ECOG ) 0 1 3 . Subjects histological cytological confirmation advance malignant melanoma , renal cell carcinoma NSCLC refractory current standard treatment indolent disease immunotherapy may beneficial 4 . Measurable disease accord irRC criterion 5 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct &lt; 2 week prior Cycle 1 : Creatinine ≤ 1.5 x upper limit normal ( ULN ) OR calculate creatinine clearance ≥ 50 ml/min Total bilirubin ≤ 1.5 x ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤ 2.5 x ULN ≤ 5 x ULN liver metastasis Absolute lymphocyte count ≥1.0 x 109/L Absolute Neutrophil Count ( ANC ) ≥1.5 x 109/L Platelets ≥100 x 109/L Haemoglobin ≥ 10 g/dL 6 . Life expectancy least 3 month 7 . An increase ≥100 γδ T cell factor i.e . ≥100 factor increase start γδ T cell number final γδ T cell number proliferation assay 5 10 day culture . 8 . Able give inform , write consent 9 . For female patient female partner male patient : must surgically sterile , postmenopausal , compliant two form contraception ( one must barrier method ) 6 month treatment period ; female patient must negative urine pregnancy test screening must breastfeed . 1 . Other primary cancer apart nonmelanoma skin cancer , carcinoma situ cervix , prior cancer treat curative intent 2 year ago without evidence recurrent disease 2 . Uncontrolled systemic infection 3 . Systemic steroid therapy immunesuppressants 4 . Treatment bisphosphonates , instance zoledronate , previous 3 month throughout trial 5 . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction within 6 month 6 . Clinicallysignificant uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation require therapy . 7 . Ulcerative Colitis / Inflammatory bowel disease , Addison 's disease 8 . Pregnancy lactation trial . A urine pregnancy test carry screen 9 . Taking investigational medicinal product ( IMP ) participation another interventional clinical trial previous 30 day 10 . Less 4 week since systemic anticancer therapy ( tyrosine kinase inhibitor , chemotherapy , immunotherapy , hormonal therapy , radiotherapy ) less 6 week since mitomycin C nitrosureas 11 . Substance abuse , medical , psychological social condition may interfere subject 's participation trial evaluation trial result 12 . Any condition consider trial physician inappropriate inclusion study contraindication leukapheresis ( contraindication heparin : recent cerebral haemorrhage ; peptic ulcer ; recent surgery eye nervous system ; hypersensitivity heparin ; past history Type II heparin induce thrombocytopenia ; past history significant spontaneous haemorrhage ; know haemophilia bleed disorder ) . 13 . Serological evidence active infection HIV , hepatitis B/C , HTLV syphilis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>